Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
By S. Nissen, K. Wolski. Archives of Internal Medicine, 2010
614 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/93c1a5f1b9cc1b4f6d254c6f1506d2142e2590cb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Molecular Biology
Citations in the corpus
- Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations (2011, methodology): “Their conclusion was based on recent observational data (42, 43) and 2 meta-analyses by Nissen and Wolski (44, 45), as well as on increased understanding of the pharmacology of rosiglitazone (46).”
- Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2013, neutral): “Although meta-analyses of smaller, underpowered studies suggested possible risk of MI with rosiglitazone (31,32), this has not been demonstrated in a larger randomized clinical trial (33,34).”
- Atherosclerosis: current pathogenesis and therapeutic options (2011, background): “, and a meta-analysis of randomized trials further revealed an increased risk for myocardial infarctio”
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012, background): “Another agent of this class, rosiglitazone, is no longer widely available owing to concerns of increased myocardial infarction risk [61].”
- Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review (2014, result): “However, some meta-analyses indicated that among patients with impaired glucose tolerance or type 2 diabetes the use of rosiglitazone for at least 12 months was associated with a significantly increased risk of myocardial infarction and heart failure, as well as with an elevated risk of cardiovascul”
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013, result): “compared with placebo, but showed benefit in its composite secondary endpoint (all-cause mortality, non-fatal MI, and stroke),(74) while rosiglitazone has been associated with an increase in myocardial infarction but not all-cause mortality.(80)”